LPL Financial’s Gain Therapeutics GANX Stock Holding History

LPL Financial’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$202K	Sell	104,251 -2,299	-2%	-$5K	﹤0.01%	5489
2025 Q4	$343K	Buy	+106,550	New	+$284K	﹤0.01%	5041

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

LPL Financial's GANX Position: Q1 2026 in Review

LPL Financial reduced its Gain Therapeutics (GANX) stake by 2.2% in Q1 2026, selling an estimated $5K and leaving 104,251 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #5489.

LPL Financial first reported a position in GANX in Q4 2025 and has held it in 2 quarters since. The position peaked at $343K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

LPL Financial held 104,251 shares of Gain Therapeutics worth $202K as of Q1 2026.
LPL Financial sold 2,299 Gain Therapeutics shares in Q1 2026, an estimated $5K.
Gain Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q1 2026, its #5489 holding.
LPL Financial first reported a position in Gain Therapeutics in Q4 2025 and has held it in 2 quarters since.
LPL Financial's Gain Therapeutics position peaked at $343K in Q4 2025.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.